Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
437.00    -9.00 (-2.02%)
Bid:
436.50
Ask:
441.50
Spread: 5.00 (1.145%)
Market Cap: £214.92m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Trading Update

25 May 2022 07:00

RNS Number : 6535M
Zotefoams PLC
25 May 2022
 

Zotefoams plc

("Zotefoams" or "Group")

 

Trading Update

 

25 May 2022 - Zotefoams, a world leader in cellular materials technology, today provides a trading update for the four months ended 30 April 2022 ahead of its Annual General Meeting to be held today at 10am at 675 Mitcham Road, Croydon, CR9 3AL.

At this meeting Steve Good, Chair of Zotefoams plc, will make the following statement:

In line with the outlook statement in our 2021 preliminary results announcement, we have experienced good demand in the first four months of 2022, resulting in Group revenue for the period being approximately 13% ahead of the comparative period.

Highlights in the period are:

Polyolefin Foams sales increased by 20%. Volumes have increased by 5%, with the majority of the sales uplift being driven by increased prices

High-Performance Products (HPP) sales increased by 6%:

Footwear sales at similar levels to prior period, as expected at this point in the demand cycle

Aviation sales improving strongly from a low base

T-FIT® insulation products sales increased by 18%

MuCell Extrusion's focus is on the technical and commercial development of ReZorce® mono-material packaging solutions, with good progress in the period

The macroeconomic environment remains difficult, with input cost inflation both significant and unpredictable and supply chains prone to disruption. We have been reacting to input-price movements by increasing our selling prices as well as focusing on internal efficiencies and controllable costs, while proactively implementing actions to mitigate supply chain risks. There has been no material disruption to the Footwear supply chain or to our major facilities in the UK, USA and Poland, although there was a 5-week enforced shutdown of our China T-FIT facility due to COVID-19.

Outlook

We have delivered good sales growth in the first four months of the year and anticipate this sales momentum to continue, supported by the price increases and a strong order book with excellent visibility to the end of June. However, we do not anticipate the challenging macroeconomic environment to ease and remain mindful of some specific risks around COVID-19.

While it is still early in the year, we anticipate Group revenue to be ahead of market expectations for the full year, with demand in line and higher prices recovering cost inflation. Current foreign exchange rates, net of hedging, may also provide some additional benefit. Consequently, we are comfortable with expectations for growth in profit and remain confident about the long-term prospects of the business.

Commenting on the update David Stirling, Group CEO of Zotefoams, said: 

"Zotefoams products are well positioned to deliver benefits to society by saving energy, protecting people and goods and helping our customers make their products using less raw material. We have invested significantly in recycling initiatives with ReZorce barrier packaging and in our core foams business, and we are well placed for future growth. The current macroeconomic climate is extremely challenging and I am proud of our team for balancing customer expectations with the cost inflation and supply chain pressures we face as a business. 

 

- Ends -

 

Enquiries:

 

Zotefoams plc

+44 (0) 208 664 1600

David Stirling, Group CEO

Gary McGrath, Group CFO

IFC Advisory

+44 (0) 203 934 6630

Graham Herring

Tim Metcalfe

Zach Cohen

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology delivering optimal material solutions for the benefit of society. Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE® polyolefin and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. Zotefoams also owns and licenses patented microcellular foam technology to reduce plastic use in extrusion applications and for ReZorce® mono-material recyclable barrier packaging.

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky, USA and Brzeg, Poland (foam manufacture), Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA (MuCell Extrusion) and Jiangsu Province, China (T-FIT).

www.zotefoams.com

AZOTE®, ZOTEK®, ReZorce® and T-FIT® are registered trademarks of Zotefoams plc.

www.zotefoams.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTKZGZKDDRGZZM
Date   Source Headline
25th Jul 20182:47 pmRNSHolding(s) in Company
16th Jul 20189:12 amRNSHolding(s) in Company
12th Jul 201811:47 amRNSDirector/PDMR Shareholding
9th Jul 20187:00 amRNSNotice of Results
12th Jun 20184:45 pmRNSDirector/PDMR Shareholding
4th Jun 20185:50 pmRNSDirector/PDMR Shareholding
4th Jun 20189:30 amRNSDirector Declaration
1st Jun 20184:39 pmRNSTotal Voting Rights
1st Jun 20184:37 pmRNSHolding(s) in Company
31st May 201811:57 amRNSDirector/PDMR Shareholding
29th May 20185:34 pmRNSDirector/PDMR Shareholding
22nd May 201812:28 pmRNSHolding(s) in Company
21st May 20184:04 pmRNSHolding(s) in Company
21st May 20187:00 amRNSDirector/PDMR Shareholding
17th May 20184:08 pmRNSHolding(s) in Company
16th May 20181:35 pmRNSResult of AGM
16th May 20187:00 amRNSCompletion of placing
15th May 20184:39 pmRNSProposed placing of shares in Zotefoams plc
14th May 20183:09 pmRNSDirector/PDMR Shareholding
13th Apr 20189:43 amRNSDirector/PDMR Shareholding
12th Apr 20182:27 pmRNS2017 Annual Report and Notice of the 2018 AGM
13th Mar 20185:30 pmRNSDirector/PDMR Shareholding
13th Mar 20187:00 amRNSFinal Results
9th Mar 20187:00 amRNSHolding(s) in Company
22nd Feb 20184:54 pmRNSHolding(s) in Company
22nd Feb 20184:48 pmRNSHolding(s) in Company
13th Feb 20187:00 amRNSDirector/PDMR Shareholding
16th Jan 20184:55 pmRNSHolding(s) in Company
12th Jan 201811:37 amRNSDirector/PDMR Shareholding
22nd Dec 201712:27 pmRNSDirector/PDMR Shareholding
21st Dec 20177:00 amRNSDirectorate Change
18th Dec 20174:10 pmRNSHolding(s) in Company
14th Dec 20177:00 amRNS£12 million investment planned at Croydon facility
13th Dec 20177:00 amRNSDirector/PDMR Shareholding
13th Dec 20177:00 amRNSStrategic Partnership with Nike
15th Nov 20177:00 amRNSDirector/PDMR Shareholding
1st Nov 20177:00 amRNSThird Quarter Trading Update
17th Oct 20171:08 pmRNSDirector/PDMR Shareholding
10th Oct 20177:00 amRNSDirector/PDMR Shareholding
28th Sep 20177:00 amRNSHolding(s) in Company
13th Sep 20177:00 amRNSDirector/PDMR Shareholding
16th Aug 20177:00 amRNSHolding(s) in Company
11th Aug 20175:23 pmRNSHolding(s) in Company
10th Aug 20177:00 amRNSDirector/PDMR Shareholding
8th Aug 20177:00 amRNSDirectorate Changes
8th Aug 20177:00 amRNSHalf-year Report
20th Jul 20177:00 amRNSHolding(s) in Company
12th Jul 201710:19 amRNSDirector/PDMR Shareholding
3rd Jul 20174:35 pmRNSPrice Monitoring Extension
13th Jun 20177:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.